Your Liver Is Talking. Here's What Your Labs Aren't Telling You.

I want to tell you something that most people leave their doctor’s office not knowing.

You can have significant liver disease with no symptoms. No pain. No yellowing skin. No dramatic sign that anything is wrong. Just a number on a lab report that gets flagged, mentioned in passing, and then filed away under “something to keep an eye on.”

I’ve had patients come to me who were told exactly that — years ago. One woman I’m thinking of had elevated liver enzymes flagged at 38, was told to cut back on alcohol even though she barely drank, and wasn’t offered any further investigation. She came to see me at 44 with fibrosis showing on imaging. Six years of watching. Six years that mattered.

That number on your lab report is not nothing. It’s your liver trying to tell you that the metabolic pressure you’ve been under has started to leave a mark.

The condition is called MASLD. You may have heard the older name: nonalcoholic fatty liver disease, or NAFLD. In 2023, a global consortium of medical societies formally renamed and redefined it — because the new name tells you exactly what this disease actually is. Metabolic dysfunction-associated steatotic liver disease. The liver problem that comes from metabolic dysfunction. Not from drinking. Not from bad luck. From the same interconnected system we’ve been talking about throughout this series.

This is not a rare diagnosis. It affects somewhere between 25 and 30 percent of the general population. Most of those people have no idea [1].

And before you decide this doesn’t apply to you because you eat reasonably well and don’t drink much — MASLD can and does develop in people with normal weight, normal cholesterol, and no obvious risk factors. If you have insulin resistance, if your blood pressure has been creeping up, if you’ve been told your triglycerides are high — your liver is in this conversation whether or not anyone has put it there [2].

Part 1: Recognizing the Pattern

Why This Gets Missed

The liver is a remarkably forgiving organ. For a long time, it absorbs the impact of metabolic stress without complaint. It doesn’t have pain receptors the way your joints or your gut do. It just quietly accumulates fat, and then — when fat accumulation triggers inflammation — it starts to scar.

The progression moves through stages: fat accumulation in liver cells, then inflammation and injury when that fat triggers an immune response, then early scarring called fibrosis, and eventually — in a smaller proportion of people — advanced irreversible scarring called cirrhosis. The first two stages are largely reversible with the right intervention. The last two are not, or only partially. This is why finding it early changes everything. And why a system that waits for symptoms before looking is failing people quietly, year after year.

Here’s what makes the pattern recognizable before it gets that far:

An elevated ALT or AST on routine bloodwork — this is often the only early signal. A lot of clinicians note it, ask about alcohol, and repeat the test in a year. That year matters more than the conversation suggests.

Fatigue that doesn’t resolve with sleep — a liver working under metabolic stress is a liver working harder than it should. The fatigue has a reason, even when the cause isn’t obvious.

A sense of fullness or mild pressure under your right ribs — the liver sits just there. When it’s enlarged from fat accumulation, some people notice it. Most don’t, which is part of the problem.

The metabolic cluster — if you have insulin resistance, type 2 diabetes, high triglycerides, low HDL, or blood pressure that keeps nudging upward, MASLD is part of the same picture. These conditions don’t travel alone because they don’t have separate causes — they share the same root. The 2024 joint guidelines from three major European medical associations now make this explicit: liver screening should happen proactively in anyone with cardiometabolic risk factors, not only once symptoms appear [2].

What’s Actually Happening

The liver is a metabolic hub. It processes fat, regulates blood sugar, filters what doesn’t belong, produces proteins your blood depends on, and manages cholesterol — among hundreds of other functions. When insulin resistance is present, the liver receives a constant, incorrect signal: keep producing glucose, keep storing fat. Over time, fat accumulates in liver cells. Not because you ate too much fat — because the signaling system is broken.

This is why MASLD connects so directly to the insulin resistance piece earlier in this series. If you read that article and recognized yourself in it, your liver is part of that story.

When fat accumulation triggers inflammation — which happens in a subset of people, and researchers are still working out exactly why some progress and others don’t — the condition becomes more serious. Inflammatory injury causes cell death, and the liver responds by laying down scar tissue. Once that scarring sets in, the window for full reversal begins to close. Which is exactly why catching this early isn’t just useful — it’s genuinely important.

Part 2: This Is Not in Your Head

What Should Have Happened at That Appointment

“Your enzymes are a bit elevated — we’ll keep an eye on it.”

I hear this from patients constantly. And what I want you to understand is that watching without investigating is not a neutral clinical act. Every year of unaddressed metabolic dysfunction is another year of potential fat accumulation, possible ongoing inflammation, and continued progression risk. The liver doesn’t repair itself while we wait.

What should have happened at that appointment, what I want to happen for every person who reads this, is a real conversation. Is there insulin resistance underneath this? What are the triglycerides doing? What’s the fasting glucose? Has anyone calculated a FIB-4 score, which can be done right now with labs you’ve probably already had, and costs nothing extra [2]?

A 2024 joint guideline from the European associations covering liver disease, diabetes, and obesity now explicitly states that non-invasive screening should be applied proactively in people with cardiometabolic risk, not reactively, after symptoms appear [2]. That is a meaningful shift in the standard of care. And it’s the kind of care that most fifteen-minute appointments haven’t caught up to yet. That gap is part of why this series exists.

I also want to address the weight piece directly, because I see the harm from the shortcut regularly. MASLD has a real association with obesity but it is not exclusively a disease of people with a high BMI. Lean MASLD is real, increasingly recognized, and in some studies carries a higher risk of progression. When a clinician attributes elevated liver enzymes to someone’s weight and stops there, a meaningful proportion of people who need further investigation get sent home instead. You’re allowed to ask for more.

The rest of this masterclass including exactly what a thorough liver workup should include, what a FIB-4 score actually tells you and what to do with it, the lifestyle interventions with the most evidence, where specific supplements genuinely fit in, and what the first FDA-approved MASH medication means for people who need it, is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from patients who feel they haven’t been given the full picture. Because usually, they haven’t.

Book a Consultation

Part 3: What Good Testing Actually Looks Like

The Tests That Tell the Real Story

A liver enzyme elevation is a starting point, not a conclusion. Here’s what actually getting to the bottom of it looks like:

Basic liver panel — ALT and AST are the primary markers of liver cell injury. GGT is often overlooked but deserves specific attention: it’s sensitive to metabolic stress and frequently rises before ALT does, making it an early signal worth tracking.

FIB-4 score — four numbers already on your labs (age, ALT, AST, platelet count) combined into a calculation that estimates how likely it is that significant fibrosis is present. Below 1.3 is reassuring. Above 2.67 warrants imaging. The space in between is where clinical judgment matters most [2]. This takes thirty seconds to calculate and is almost never done proactively. Ask for it by name.

Fasting insulin and HOMA-IR — because assessing the liver without looking at the metabolic driver underneath is an incomplete assessment. These numbers tell me what’s fueling the problem.

Fasting lipids including triglycerides — triglycerides above 150 mg/dL are a meaningful metabolic signal. In the context of elevated liver enzymes, they shift the picture substantially.

Liver ultrasound — widely available, non-invasive, and able to detect fat accumulation when it’s significant. It’s a useful first look, but it doesn’t measure fibrosis. Think of it as opening the door, not reading the whole room.

FibroScan (transient elastography) — this is where the picture sharpens. It uses sound waves to measure liver stiffness, which correlates directly with the degree of scarring. The 2024 guidelines identify it as the preferred non-invasive fibrosis assessment for anyone with an intermediate or high FIB-4 [2]. If you’ve never been offered this and your numbers are in the grey zone, it’s worth asking about specifically.

MRI-PDFF — when more precise fat quantification is needed, MRI-based proton density fat fraction is the most accurate non-invasive option. Typically used in specialist settings or when earlier imaging is ambiguous.

Liver biopsy remains the technical gold standard but the 2024 guidelines reflect where the field is moving: toward validating non-invasive tools precisely because biopsy is invasive, carries real risk, and is unnecessary for most people. Accurate staging without unnecessary procedures is now achievable for the majority of patients [2].

Part 4: What Actually Moves the Needle

Start With the Metabolic Foundation

MASLD is a metabolic disease. Treating it metabolically is not an integrative workaround — it is the explicit first-line recommendation across every major guideline.

Weight loss, when it’s part of the picture, is the most powerful single lever. A 5% reduction in body weight meaningfully reduces liver fat. A 7–10% reduction reduces inflammation and improves the cellular picture. Getting to 10% or more can actually reverse early fibrosis — the liver rebuilding itself in response to a changed metabolic environment [2]. I find that genuinely remarkable every time I explain it to a patient. The liver is trying to heal. We’re just giving it the conditions to do so.

But weight loss is the outcome, not the method. The method is what actually gets you there.

Dietary pattern matters more than any single food rule. The Mediterranean pattern has the most consistent evidence in MASLD — not because of any one ingredient, but because of the overall composition: abundant vegetables, legumes, whole grains, fish, and olive oil; limited ultra-processed foods, refined carbohydrates, and added sugar. That last one deserves its own moment.

Fructose is metabolized almost entirely in the liver. Unlike glucose, which distributes broadly, fructose goes straight to the liver and directly promotes fat accumulation there. This is not a reason to eliminate whole fruit — the fiber and micronutrients in whole fruit substantially change how it’s processed. It is a reason to look hard at sweetened beverages, fruit juices, and anything with added sugar. These aren’t abstract risks. They are a direct metabolic burden on the organ we’re trying to support [2].

And here’s something I genuinely enjoy telling patients: coffee is good for your liver. Multiple studies show that regular coffee consumption is associated with slower fibrosis progression in MASLD. Two to three cups of regular coffee daily appears to have a real hepatoprotective effect, likely through antioxidant and anti-inflammatory mechanisms. It’s consistent enough that it now appears in clinical guidance [2]. One of the more pleasant recommendations in my toolkit.

Movement helps even when the scale doesn’t move. Both aerobic exercise and resistance training reduce liver fat independently of weight loss. This matters — it means that getting active is doing something real at the cellular level even when bodyweight stays the same. 150 minutes of moderate activity per week is the guideline minimum; more appears to produce additional liver benefit.

Alcohol is not neutral here, even in moderate amounts. Current guidelines advise minimizing alcohol intake — not just avoiding heavy drinking. A liver under metabolic stress handles even moderate alcohol differently than a healthy liver. Most patients haven’t been told this.

Where Supplements Fit In

Before I recommend any supplement, I run a thorough micronutrient assessment. What I find shapes what I suggest. These are the ones with the clearest evidence specifically in the MASLD context:

Vitamin E (800 IU daily) has been shown in clinical trials to reduce liver inflammation and improve the cellular picture of MASH in non-diabetic adults — and it’s one of the few supplements that has earned its way into formal clinical guidelines [3]. High-dose vitamin E should always be used with clinical oversight, and it isn’t appropriate for everyone. But for the right patient, it’s a meaningful intervention.

Omega-3 fatty acids (EPA and DHA) reduce fat accumulation in the liver, which is a real effect in early-stage disease. They don’t address inflammation or fibrosis as consistently, but for someone with steatosis and elevated triglycerides, the case for them is solid [3].

Berberine is the one I’m probably most enthusiastic about in this context. It improves insulin sensitivity, reduces triglycerides, and has been shown in clinical trials to reduce liver fat and improve liver enzymes in MASLD. It works through the same cellular pathway as metformin — which is exactly why I take it seriously clinically, not just because it comes from a plant [3]. For patients where metformin isn’t the right fit, berberine is a genuinely defensible option.

Silymarin (milk thistle) — I’ll be honest: the evidence here is more mixed than the wellness world suggests. Standardized silymarin preparations have shown modest benefit in reducing liver enzymes and oxidative stress. It’s not a primary intervention. As part of a broader protocol, it has a supporting role [3].

When Medication Is the Right Answer

In March 2024, the FDA approved resmetirom (Rezdiffra) — the first medication ever specifically approved for the treatment of MASH with moderate to advanced fibrosis [4]. For patients who have been in the watching-and-waiting pattern with established disease, this is a genuine milestone.

Resmetirom works by activating a specific thyroid receptor in the liver that regulates fat metabolism — reducing liver fat and inflammation without affecting the thyroid system elsewhere in the body. It demonstrated meaningful fibrosis improvement in clinical trials and earned its approval on that basis [4].

It isn’t for everyone. It’s specifically indicated for non-cirrhotic MASH with fibrosis at stages F2 or F3. Most people with MASLD — those in earlier stages — are still best served by the metabolic and lifestyle interventions above. But knowing this option exists matters, especially for anyone who has been waiting.

GLP-1 medications (semaglutide, tirzepatide) also belong in this conversation. They weren’t designed as liver medications, but the metabolic improvements they produce — reduced weight, improved insulin sensitivity, lower triglycerides — translate directly into liver benefit. The 2024 guidelines explicitly recommend them for MASLD management in patients with comorbid diabetes or obesity [2].

Part 5: Retesting and What to Watch

The 6-Month and Annual Check-In

Liver healing moves more slowly than hormonal change. Meaningful reassessment takes time.

At six months, I want to see liver enzymes (ALT, AST, GGT), fasting insulin, and triglycerides. Are the numbers moving in the right direction? Even a 20–30% reduction in ALT tells me the intervention is working, even if the number is still elevated.

At twelve months, anyone who started with an intermediate or elevated FIB-4 should have it recalculated. If a FibroScan was done at baseline, a repeat at one year gives real data about whether the liver is responding.

If you’re on resmetirom, liver function testing at 4–8 weeks after starting, then every three months. The monitoring schedule here is specific and important [4].

Between labs, track your energy, any right-sided abdominal fullness, and how your metabolic symptoms feel overall. The liver doesn’t produce dramatic warning signs in early disease — which is exactly why we monitor the surrounding picture as a proxy.

Come back sooner than scheduled if your enzymes double from baseline, you develop new pain under your right ribs, your fatigue suddenly worsens without explanation, or you notice any yellowing of the skin or whites of your eyes. That last one doesn’t wait for a scheduled appointment.

What to Ask For

If you’ve been told your enzymes are elevated and nothing more was done — that’s the conversation worth revisiting. Ask specifically for a FIB-4 calculation, fasting insulin, and a liver ultrasound if one hasn’t been done. These aren’t specialist-only tests. They’re the starting point for actually understanding what’s happening.

If your FIB-4 comes back above 1.3, ask about FibroScan or a referral to a hepatologist. Not because you have cirrhosis. Because knowing your stage is what makes the rest of the plan make sense.

Where to Go From Here

MASLD is not a verdict. It’s a signal — and for most people reading this, it’s a signal that arrived early enough to change what happens next. The liver’s capacity for recovery, when the metabolic environment genuinely shifts in its favor, is one of the things I find most remarkable in this work. Given the right conditions, the liver heals. The science on this is not uncertain.

If you’ve had an enzyme elevation noted and nothing further was done, that’s worth revisiting — not with anxiety, but with the quiet confidence that comes from understanding what you’re actually dealing with. If you have insulin resistance, elevated triglycerides, or blood pressure that keeps creeping up, your liver is in this conversation even if no one has put it there yet.

That’s what we’re here to change.

If any of this resonated and you want to understand what your picture actually looks like, that’s exactly the kind of conversation we have.

Book a Consultation with Heal Integrative Wellness